CORT
NASDAQCorcept Therapeutics Incorporated
News · 26 weeks87+77%
2025-12-142026-06-07
Mix5190d
- Insider29(57%)
- Other10(20%)
- SEC Filings8(16%)
- Analyst2(4%)
- Earnings2(4%)
Latest news
25 items- PRCorcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym®New data from CATALYST and MOMENTUM trials presented at American Diabetes Association's (ADA) 86th Scientific Sessions In the CATALYST trial, patients with hypercortisolism treated with Korlym exhibited clinically and statistically significant improvements in hemoglobin A1c (HbA1c) and clinically meaningful reductions in body weight, body mass index and waist circumference, with numerically greater benefit in those taking GLP-1 receptor agonists or tirzepatide Late-breaking data from the MOMENTUM trial confirm high prevalence of endogenous hypercortisolism in patients with type 2 diabetes and resistant hypertension Corcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stag
- INSIDERChief Development Officer Guyer William exercised 20,000 shares at a strike of $21.65 and sold $1,412,000 worth of shares (20,000 units at $70.60) as part of a pre-agreed trading plan (SEC Form 4)4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
- INSIDEROfficer Lyon Joseph Douglas was granted 1,074 shares and covered exercise/tax liability with 269 shares, increasing direct ownership by 13% to 7,035 units (SEC Form 4) (tax liability)4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
- INSIDERChief Development Officer Guyer William was granted 1,754 shares, increasing direct ownership by 79% to 3,985 units (SEC Form 4)4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
- INSIDEROfficer Maduck Sean exercised 25,000 shares at a strike of $8.27, sold $1,755,183 worth of shares (25,000 units at $70.21) as part of a pre-agreed trading plan, was granted 1,230 shares and covered exercise/tax liability with 452 shares, increasing direct ownership by 9% to 9,755 units (SEC Form 4) (for withholding tax)4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
- INSIDERChief Financial Officer Mokari Atabak exercised 40,000 shares at a strike of $19.26, sold $2,800,004 worth of shares (40,000 units at $70.00) as part of a pre-agreed trading plan, was granted 1,268 shares and covered exercise/tax liability with 395 shares, increasing direct ownership by 6% to 16,130 units (SEC Form 4) (tax withholding)4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
- INSIDERChief Business Officer Robb Gary Charles was granted 1,552 shares and covered exercise/tax liability with 358 shares, increasing direct ownership by 5% to 25,681 units (SEC Form 4) to satisfy tax liability4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
- SECSEC Form 8-K filed by Corcept Therapeutics Incorporated8-K - CORCEPT THERAPEUTICS INC (0001088856) (Filer)
- INSIDERChief Executive Officer Belanoff Joseph K gifted 300,000 shares, received a gift of 300,000 shares and sold $895,252 worth of shares (12,837 units at $69.74) as part of a pre-agreed trading plan (SEC Form 4)4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
- INSIDEROfficer Lyon Joseph Douglas sold $325,000 worth of shares (5,000 units at $65.00), decreasing direct ownership by 45% to 6,230 units (SEC Form 4)4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
- INSIDEROfficer Maduck Sean exercised 75,000 shares at a strike of $8.27 and sold $4,918,944 worth of shares (75,000 units at $65.59) as part of a pre-agreed trading plan (SEC Form 4)4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
- INSIDERDirector Wilson James N received a gift of 9,011 shares and gifted 901,067 shares (SEC Form 4)4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
- PRCorcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane ExposureCorcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today presented new overall survival data from its pivotal Phase 3 ROSELLA trial of Lifyorli™ (relacorilant) plus nab-paclitaxel (a taxane chemotherapy) in an oral presentation at the ASCO 2026 (American Society of Clinical Oncology) Annual Meeting. In ROSELLA, patients treated with Lifyorli combined with nab-paclitaxel experienced a 35 percent reduction in the risk of death compared to patients treated with nab-paclitaxel alone (ha
- SECSEC Form S-8 filed by Corcept Therapeutics IncorporatedS-8 - CORCEPT THERAPEUTICS INC (0001088856) (Filer)
- SECCorcept Therapeutics Incorporated filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - CORCEPT THERAPEUTICS INC (0001088856) (Filer)
- PRCorcept to Resubmit its New Drug Application for Relacorilant as a Treatment for Patients with Cushing's SyndromeCorcept Therapeutics Incorporated (NASDAQ:CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced it will resubmit its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for relacorilant as a treatment for patients with Cushing's syndrome. "Following issuance of its complete response letter, the FDA asked us to conduct additional analyses of our NDA data," said Joseph K. Belanoff, M.D., Corcept's Chief Executive Officer. "Based on the positive outcome of those analyses and the productive te
- INSIDERSEC Form 4 filed by Director Baker G Leonard Jr4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
- INSIDERSEC Form 4 filed by Director Alton Gregg H4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
- INSIDERSEC Form 4 filed by Director Wilson James N4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
- INSIDERSEC Form 4 filed by Director Swisher Daniel N Jr4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
- INSIDERSEC Form 4 filed by Director Murray Joshua M.4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
- INSIDERSEC Form 4 filed by Director Mahoney David L4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
- INSIDERSEC Form 4 filed by Director Park Kimberly4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
- INSIDERChief Business Officer Robb Gary Charles received a gift of 2,000 shares and gifted 5,300 shares, decreasing direct ownership by 18% to 24,487 units (SEC Form 4)4 - CORCEPT THERAPEUTICS INC (0001088856) (Issuer)
- ANALYSTCorcept Therapeutics upgraded by UBS with a new price targetUBS upgraded Corcept Therapeutics from Neutral to Buy and set a new price target of $72.00
CORT FAQ
7 questionsWhat does Corcept Therapeutics Incorporated do?
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in...Where does CORT stock trade?
Corcept Therapeutics Incorporated (CORT) is listed on NASDAQ.What sector and industry is CORT in?
Corcept Therapeutics Incorporated operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Corcept Therapeutics Incorporated go public?
Corcept Therapeutics Incorporated (CORT) completed its IPO in 2004.What are analysts saying about CORT?
Corcept Therapeutics Incorporated has had 8 recent analyst actions on file. The most recent action was from UBS: Buy on 2026-05-13. Recent price targets range from $2500.00 to $3800.00.What companies are similar to CORT?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare CORT side-by-side with any of them on Quantisnow.How can I track CORT on Quantisnow?
Quantisnow aggregates Corcept Therapeutics Incorporated's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CORT to receive live email and push alerts on every new disclosure.